SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.... Read More

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platform Enrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of... Read More

SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [ 212 Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients... Read More

SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor... Read More

SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press... Read More

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.... Read More

Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed... Read More

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [ 212 Pb]VMT-α-NET ( NCT05636618 ) has been accepted as a poster presentation... Read More

Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its next generation targeted radiopharmaceutical technology platform Four additional new assets being evaluated for IND development, to be guided by first-in-human images Making progress on plans to expand manufacturing capabilities by... Read More

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at... Read More

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.... Read More

[ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi) Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction of tumor volume, one of whom had a confirmed response as defined by RECIST v1.1. Signal of anti-tumor activity was generally more pronounced in patients with lower body weight... Read More

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [ 212 Pb]VMT-α-NET at the 2024 North American... Read More

Advancing investigation of [ 212 Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21 st International Congress of the Society of Melanoma Research in October Presenting initial results from the company-sponsored Phase 1/2a study of [ 212 Pb]VMT-α-NET in patients with RPT-naïve... Read More

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will... Read More

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.... Read More

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company’s radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in... Read More

[ 212 Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi) Prolonged progression-free survival and tumor response were observed in heavily pretreated patients who received the low (3.0 mCi) dose of [ 212 Pb]VMT01, consistent with preclinical findings Trial is progressing with testing [ 212 Pb]VMT01 at a lower (1.5mCi) dose to further elucidate the optimal... Read More

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [ 212 Pb]VMT01 have been selected for a poster presentation at the 21 st International Congress of the Society for... Read More

SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit... Read More

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held... Read More

SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress (WMIC) 2024, held on September 9-13, 2024, in Québec,... Read More

SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212 Pb VMT01 for the diagnosis and treatment of patients... Read More

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.... Read More

Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials On track to advance multiple pre-IND assets into the clinic in the next 12-18 months Making continued progress on build out of manufacturing infrastructure Cash, cash equivalents and short-term investments balance of approximately $293 million expected to be sufficient to fund our current planned operations and capital investments... Read More

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel... Read More

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom... Read More

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024,... Read More

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was... Read More

SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common... Read More

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company’s sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual... Read More

Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials Disclosed a new internally discovered molecule that targets fibroblast activation protein-α Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sites Raised $177.2 million in gross proceeds through various financing transactions and raised an additional $49.5 million subsequent to March 31... Read More

SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one... Read More

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of... Read More

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [ 212 Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in... Read More

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled... Read More

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals... Read More

SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [ 212 Pb]VMT01 in combination... Read More

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here . The event... Read More

SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203 Pb- and 212... Read More

SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate... Read More

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024. Fireside Chat with JonesResearch – February 28, virtual... Read More

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present virtually at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024,... Read More

Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide Targeting Receives up to $2.4M NIH Grant to Develop Differentiated Antibody-based Radiopharmaceutical Approach SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment... Read More

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously announced underwritten public offering of (i) 156,399,542 shares of its common stock at the public offering price of $0.37 per share,... Read More

SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten public offering of 132,075,218 shares of its common stock at a public offering price of $0.37 per share and, to certain investors in lieu... Read More

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public offering of shares of its common stock, and, to certain investors in lieu of common stock, pre-funded warrants to purchase... Read More

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [ 212 Pb]VMT-α-NET and [ 212 Pb]VMT01, after the safety monitoring committees for each study unanimously recommended moving forward. In addition, the first patient in cohort 2 of... Read More

Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NET Lantheus will have the option to co-fund and negotiate an exclusive license for certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s lead platform technology Lantheus agrees to invest up to approximately $33 million in Perspective Therapeutics equity subject to Perspective... Read More

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67 Cu and 203/212 Pb double chelator design. PSMA Alpha-PET DoubLET licensing provides Perspective with a strongly differentiated prostate cancer program SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the... Read More

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT. Management will also participate at investor conferences alongside the J.P. Morgan... Read More

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”). The transaction is expected to close in the first quarter of 2024 and is subject to customary... Read More

First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [ 212 Pb]VMT-α-NET Preliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial... Read More

Imaging was conducted as part of a clinical study at Technical University of Dresden in Germany Image was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular Imaging , November 2023 Radiolabeling was performed on-site using a Company-provided generator SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today... Read More

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals. “The results from these preclinical studies are compelling and continue to... Read More

SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors (NETs). This milestone follows the recent completion of the first dose escalation cohort for Perspective’s... Read More

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights.. “Our commitment to advancing targeted alpha-particle therapies against neuroendocrine tumors remains steadfast as we have completed dosing of the first patient in the Phase 1/2a clinical trial of [ 212... Read More

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington University in St Louis in the Company’s Phase 1/2a trial evaluating the safety and efficacy of [ 212 Pb]VMT-α-NET, a targeted alpha-particle therapy (TAT), in patients with unresectable or metastatic somatostatin receptor type 2... Read More

SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212 Pb-VMT01 (clinicaltrials.gov identifier NCT05655312 ), its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma. “We are... Read More

SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or... Read More

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as... Read More

Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease . SEATTLE, Wash., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of encouraging... Read More

[ 212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [ 212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic neuroblastoma SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the... Read More

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS). The conference is being held in Prague, Czech Republic, from September 5-9, 2023. “We are pleased with... Read More

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212 Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36 th Annual Congress of the European Association of Nuclear Medicine (EANM). The conference is being held in Vienna, Austria,... Read More

First patient with MC1R-positive metastatic melanoma treated with 2 12 Pb-VMT01 Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at the University of Wisconsin in the Company’s Phase 1/2a dose escalation trial... Read More

Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023. First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE... Read More

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced a collaborative initiative focused on increasing access to... Read More

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the... Read More

VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with [ 203 Pb]VMT01 to determine eligibility for [ 212 Pb]VMT01 treatment. Preliminary results from initial cohorts expected by end of 2023. RICHLAND, WASHINGTON & CORALVILLE, IOWA , June 21, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.... Read More

RICHLAND, Wash & CORALVILLE, IOWA, June 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that the growing body of information regarding Cesium-131 brachytherapy in the treatment of prostate... Read More

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will have four presentations at the 2023 Annual Society for... Read More

Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 2 03 Pb manufacturing, and In Vivo Distribution of Recoiled 213 Bi from [ 225 Ac]Ac-DOTATATE RICHLAND, WASHINGTON & CORALVILLE, Iowa, May 24, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE... Read More

Additional CDMO capabilities added to increase availability of clinical trial product in the US Phase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and... Read More

Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the Committee Michael McCormick announced his resignation and amicable departure from the Board of Directors RICHLAND, WA & CORALVILLE, IA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company... Read More

BOCA RATON, Fla. and RICHLAND, Wash. , March 14, 2023 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and manufacturing organization and radiopharmaceutical manufacturer, today announces the signature of a Master Services Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned subsidiary of Perspective Therapeutics, Inc. ("Perspective") (NYSE AMERICAN: CATX), for... Read More

RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Perspective, Therap e utics, Inc. (formerly known as “Isoray, Inc.”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results... Read More

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three... Read More

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint... Read More

RICHLAND, Wash. & CORALVILLE, Iowa / Feb 06, 2023 / Business Wire / Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that... Read More

RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation... Read More

RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal... Read More

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company's... Read More

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company’s... Read More